| Webster County Community Hospital | |
| P O Box 465, 621 N Franklin St, Red Cloud, Nebraska 68970 | |
| (402) 746-5600 | |
| Not Available |
| Name | Webster County Community Hospital |
|---|---|
| Type | Critical Access Hospital |
| Location | P O Box 465, 621 N Franklin St, Red Cloud, Nebraska |
| Ownership | Government - Local |
| Emergency Services | Yes |
| Medicare ID (CCN) | 281316 |
| NPI Number | 1811968076 |
| Organization Name | WEBSTER COUNTY COMMUNITY HOSPITAL |
| Address | 6th Street And Franklin Street, Red Cloud, NE 68970 |
| Hospital Type | General Acute Care Hospital - Critical Access |
| Phone Number | 402-746-5600 |
News Archive
A study conducted at the Research Institute of the McGill University Health Centre suggests screening breast cancer patients for the prolactin receptor could improve the prognosis for patient and may help them avoid unnecessary and invasive treatments
The U.S. Food and Drug Administration has approved tetrabenazine, the first drug approved for use in the United States to treat Huntington's disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease.
MAP Pharmaceuticals, Inc. today announced financial results for the first quarter ended March 31, 2012.
Shire plc, the global specialty biopharmaceutical company, announces that its subsidiaries Shire Development Inc. and Shire Pharmaceutical Development Inc. have filed a lawsuit in the U.S. District Court for the District of Delaware against Cadila Healthcare Limited, doing business as Zydus Cadila and Zydus Pharmaceuticals, Inc. for the infringement of U.S. Patent No. 6,773,720.
› Verified 1 days ago
| Able to receive lab results electronically | No |
| Able to track patients' lab results, tests, and referrals electronically between visits | No |
News Archive
A study conducted at the Research Institute of the McGill University Health Centre suggests screening breast cancer patients for the prolactin receptor could improve the prognosis for patient and may help them avoid unnecessary and invasive treatments
The U.S. Food and Drug Administration has approved tetrabenazine, the first drug approved for use in the United States to treat Huntington's disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease.
MAP Pharmaceuticals, Inc. today announced financial results for the first quarter ended March 31, 2012.
Shire plc, the global specialty biopharmaceutical company, announces that its subsidiaries Shire Development Inc. and Shire Pharmaceutical Development Inc. have filed a lawsuit in the U.S. District Court for the District of Delaware against Cadila Healthcare Limited, doing business as Zydus Cadila and Zydus Pharmaceuticals, Inc. for the infringement of U.S. Patent No. 6,773,720.
› Verified 1 days ago
Webster County Community Hospital Critical Access Hospital Location: P O Box 465, 621 N Franklin St, Red Cloud, Nebraska 68970 Phone: (402) 746-5600 |